+

WO2006107718A2 - Produit de diffusion de la lumiere permettant de classer des traitements contre le vih/sida - Google Patents

Produit de diffusion de la lumiere permettant de classer des traitements contre le vih/sida Download PDF

Info

Publication number
WO2006107718A2
WO2006107718A2 PCT/US2006/011751 US2006011751W WO2006107718A2 WO 2006107718 A2 WO2006107718 A2 WO 2006107718A2 US 2006011751 W US2006011751 W US 2006011751W WO 2006107718 A2 WO2006107718 A2 WO 2006107718A2
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
signal
control
cells
sample
Prior art date
Application number
PCT/US2006/011751
Other languages
English (en)
Other versions
WO2006107718A3 (fr
Inventor
Satish Deshpande
Original Assignee
Estill, Mark T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estill, Mark T filed Critical Estill, Mark T
Publication of WO2006107718A2 publication Critical patent/WO2006107718A2/fr
Publication of WO2006107718A3 publication Critical patent/WO2006107718A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G01N21/4788—Diffraction

Definitions

  • the product uses light scattered by blood from a person infected with at least one variant of the human immunodeficiency virus with - and without - candidate treatments added in order to rank the potency of the candidate treatments specifically forlhe person.
  • FIG. 1 shows the ranking schematically.
  • FIG. 2 shows the light scattering schematically.
  • the product comprises a ranking signal 40 which ranks the potency of antiviral treatments from a treatment plurality of antiviral treatments.
  • the ranking signal is caused by at least a control signal 13 and by at least a subset of a treatment signal plurality 30.
  • the ranking signal represents at least comparisons between at least some of the subset of the treatment signal plurality and the control signal.
  • the subset necessarily has more than one member of the treatment signal plurality.
  • the control signal 13 represents at least a control measurement of a control scattered light intensity distribution.
  • the control scattered light intensity distribution comprises control incident light scattered 14 by a control sample of cells 12.
  • the control sample 12 comprises a control plurality of sample cells from a sample 11 of cells.
  • the sample of cells comprises cells from blood of a person infected with at least one variant of human immunodeficiency virus variants.
  • the treatment signal plurality 20 represents at least a plurality of treatment measurements of a treatment distribution plurality of treatment scattered light intensity distributions.
  • the treatment distribution plurality 30 comprises treatment incident light scattered respectively from each Ith member of a treatment sample plurality of treatment samples of cells.
  • Each Ith member of the treatment sample plurality comprises an Ith treatment plurality of cells from the sample of cells with an Ith treatment from a treatment plurality of antiviral treatments added.
  • the control incident light and the treatment incident light can be from two separate light sources, can be from the one light source, and can be from portions of one light source.
  • the control measurement and the treatment measurements can be made by two, and more, separate imagers, can be one imager, and can be portions of one imager.
  • the control scattered light intensity distribution and the treatment distribution plurality can be obtained in serial measurements, in one multi-component measurement, by beam splitting means, and in combinations of these.
  • 'Imager' means any device which can measure light intensity.
  • control signal and the treatment signal plurality must be comparable. This can be achieved in various ways.
  • the conditions of the imagings can be interchangeable, except for the added treatment, so that the control signal and members of the treatment signal plurality light are directly comparable.
  • imagings can be calibrated with a standard imaging, so that the control signal and members of the treatment signal plurality are comparable via calibrations.
  • control scattered light intensity distribution and the treatment distribution plurality are obtained using the light scattering taught in US patent application 10/416,099 filed 06 May 2003 published as US20040043433-A1 on 04 March 2004, which is incorporated herein by reference, and which is a 371 of PCT application PCT/ US02/02132 filed 25 January 2002 and published as WO02/077748 03 October 2002, which claims priority of US provisional application 60/265,761 filed 01 February 2001.
  • FIG. 2 The light scattering is shown schematically in FIG. 2. Relative to orthogonal axis triad 101, 102, 103, a sensitive surface 62 of an imager is parallel to the 101, 102 plane and orthogonal to the 103 axis. The central ray 123 of incident light is parallel to the 103 axis. A scattered ray of light 125 which is scattered by a control or treatment sample 61 is at an angle 126 from the central ray 123 and intersects the sensitive surface 62 at a line 121 which extends between edges 127 and 128 of the sensitive surface and which is parallel to the 101 axis.
  • values of the scattered light intensity detected by the imager can be averaged along the 121 line and can be averaged for multiple exposures of the imager. This is repeated for multiple values of the scattering angle 126.
  • the result is the control scattered light intensity distribution for the control sample when 61 is the control sample.
  • the result is the Ith member of the treatment distribution plurality when 61 is the Ith member of the treatment sample plurality.
  • Scattered light can illuminate a screen which can be imaged. Scattered light can be imaged directly.
  • Incident light in the range 780 to 820 nanometers works well because this minimizes absorption and anomalous dispersion.
  • the incident light wavelength can be tailored within this range and outside of this range to meet various needs.
  • Off-the-shelf imagers sensitive in the near infrared work well. Imagers with more sophisticated read out capacity can be used in more automated versions of the product.
  • angular intensity distributions to an angle of about 5 degrees produce useful results. Useful results can also be obtained from distributions extending to larger angles.
  • a beam stop can intercept the central portion of light to protect the imager so that about the first 0.5 degrees of the angular distribution is intercepted.
  • Other instrumentation designs could reduce the amount of intercepted angular distribution in order to get better data.
  • the wave front of the scattered light is spherical.
  • the imaging surface can be spherical
  • the imaging data can be corrected for a non-spherical imaging surface
  • the thickness of all the samples along the central axis of the input light can be small enough so that it is not necessary to correct for the non-spherical shape of the imaging surface.
  • the correction is unnecessary at one millimeter sample thickness and necessary at five millimeters sample thickness.
  • Treatment samples can have combinations of antivirals added to cells from the sample.
  • Antivirals can be in gels so that treatment samples are formed by adding cells from the sample to the gels.
  • Members of the array 40 shown in FIG. 1 can be Pearson's rank coefficients and can be Spearman's rank coefficients.
  • the bottom CS row 41 shows the rank coefficients - RCl through RCN - which are for the control signal CS paired in turn with each member of a treatment signal plurality TS 1 through TSN. The lowest rank coefficient in this row indicates! the member of the treatment plurality which is most potent for this particular sample of blood.
  • the TSN row -just above 41 - shows the rank coefficients for the TSN treatment signal paired with each of the other members of the treatment signal plurality.
  • the TSI row 42 shows the rank coefficients for the Ith member of the treatment signal plurality paired with other members of the treatment signal plurality. (The array is symmetric about the diagonal with rank coefficients of 1.)
  • the highest of the rank coefficients in all but the bottom CS row indicates the member of the treatment plurality which is most alike the most potent treatment and can be usefully combined with the most potent.
  • the control sample can be from the sample with a control treatment added.
  • the control sample can be from the sample with a plurality of control treatments added.
  • the control signal is caused by the control imager when the control imager detects the control scattered light intensity distribution. This can happen in multiple iterations.
  • a component of the control signal from an iteration can be signal connected with an information system via a signal connection.
  • the information system can use multiple components from the multiple iterations to cause the control signal.
  • the information system can be remote from the control imager.
  • the signal connection can be wired, wireless, and combinations of these.
  • the treatment signal plurality can be caused in the same manner.
  • the ranking signal can be caused by the information system.
  • Transmitted signals can be any of various point-to-point and broadcast fo ⁇ ns of energy transmission such as wireless and via wires, cables, and fibers. Parts of transmitted signals can reside with one form of the transmitted signal, parts can reside with a second form of transmitted signal, and parts can reside with various combinations of transmitted signals.
  • Direct causal means and transmission means can be any means by which a first physical state can produce a second physical state.
  • these can be - but are not limited to - mechanical means, pneumatic means, acoustic means, electromagnetic means, entanglement means, and combinations of two and more of these.
  • the processing can utilize configured processing elements such as fixed circuits, can utilize configurable processing elements such as field programmable gate arrays and neural networks, can utilize instructions in a signal-bearing medium, and can utilize combinations of these.
  • the processing can be by stand alone means, can act via a local information system, can act via a networked info ⁇ nation system, and can act via combinations of these.
  • the processing - in part at least - can be by parts of an imager.
  • the signal-bearing medium can be a transmitted signal, a storage medium, and a combination of a transmitted signal and a storage medium.
  • the light scattering product ranking HIV/AIDS treatments comprises a device which produces the ranking signal and comprises the method by which the device produces the ranking signal.
  • the product can use any means to prepare the control sample and the treatment sample plurality, to cause the control signal and the treatment signal plurality by light scattering, and to use the control signal and the treatment signal plurality to cause the ranking which cause functionally equivalent results.

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention consiste à comparer les distributions angulaires d'intensité de la lumière diffusée par des cellules issues du sang d'une personne infectée par au moins l'un des virus VIH/SIDA auquel est ajouté ou non un traitement sélectionné parmi une pluralité de traitements antiviraux, afin de classer la puissance des traitements pour ladite personne, la comparaison pouvant comporter des calculs de coefficients de corrélation.
PCT/US2006/011751 2005-04-06 2006-03-31 Produit de diffusion de la lumiere permettant de classer des traitements contre le vih/sida WO2006107718A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66919105P 2005-04-06 2005-04-06
US60/669,191 2005-04-06

Publications (2)

Publication Number Publication Date
WO2006107718A2 true WO2006107718A2 (fr) 2006-10-12
WO2006107718A3 WO2006107718A3 (fr) 2008-01-03

Family

ID=37073960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/011751 WO2006107718A2 (fr) 2005-04-06 2006-03-31 Produit de diffusion de la lumiere permettant de classer des traitements contre le vih/sida

Country Status (1)

Country Link
WO (1) WO2006107718A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1366409A4 (fr) * 2001-02-01 2007-03-28 Carrick Bruce Determination d'activites therapeutiques par diffusion de la lumiere

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4907235A (en) * 1988-04-01 1990-03-06 Laserscope Intra-cavity beam relay for optical harmonic generation
US5718241A (en) * 1995-06-07 1998-02-17 Biosense, Inc. Apparatus and method for treating cardiac arrhythmias with no discrete target
US20040043433A1 (en) * 2002-01-25 2004-03-04 Satish Deshpande Light scatering determination of treatment potencies
JP3826721B2 (ja) * 2001-04-03 2006-09-27 株式会社日立製作所 細菌検査システム

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1366409A4 (fr) * 2001-02-01 2007-03-28 Carrick Bruce Determination d'activites therapeutiques par diffusion de la lumiere

Also Published As

Publication number Publication date
WO2006107718A3 (fr) 2008-01-03

Similar Documents

Publication Publication Date Title
US20220011162A1 (en) Spectrometry system with visible aiming beam
Sluse et al. A quadruply imaged quasar with an optical Einstein ring candidate: 1RXS J113155. 4–123155
KR20190064682A (ko) 휴대용 분광계
GB2543655A (en) Spectrometry system and method, spectroscopic devices and systems
CN102755167A (zh) 非侵入式血糖监测装置与方法以及生化分子的分析方法
TW201135213A (en) Multi-channel optical cell
CN103767682B (zh) 太赫兹光谱成像系统和方法
CN107076613A (zh) 光谱测定方法及光谱测定装置
CN111989575B (zh) 散射光信号测量设备和信息处理设备
US12201396B2 (en) Optical speckle receiver
JP2022534950A (ja) 画角に伴って照射波長を変更するアクティブ照射システム
CN113015882A (zh) 用于确定至少一个对象的位置的测量头
US9042694B2 (en) Energy target system
CN218512314U (zh) 一种基于超透镜的拉曼光谱仪探头及光学系统
EP2728336B1 (fr) Appareil de mesure optique et procédé de mesure optique
WO2006107718A2 (fr) Produit de diffusion de la lumiere permettant de classer des traitements contre le vih/sida
CN103908264B (zh) 非侵入式葡萄糖监测装置
KR102454950B1 (ko) 분광기 및 분광기를 포함하는 이미지 센서
TW201424690A (zh) 非侵入式葡萄糖監測裝置
US12109006B2 (en) Optical speckle receiver
CN108387538B (zh) 光谱仪和使用光谱仪测量生物成分的设备
US20080291432A1 (en) System and method for monitoring the coupling efficiency of a fiber-optic surgical system
WO2019073881A1 (fr) Dispositif d'imagerie et dispositif de traitement d'image
KR102064971B1 (ko) 이미지 획득 장치
EP2749218B1 (fr) Appareil de surveillance non invasive du glucose

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06740104

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载